Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia . The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. An oral pharmaceutical composition in a capsule or microcapsule adapted for enteric delivery and comprising a plurality of viable non-pathogenic or attenuated pathogenic Clostridium spores, a plurality of viable non-pathogenic or attenuated pathogenic Bacteroides , and a plurality of viable non-pathogenic or attenuated pathogenic Escherichia coli , wherein said oral pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes or between about 10 9 and about 10 11 viable microbes.
2. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for treating a Clostridium difficile infection.
3. An oral pharmaceutical composition in a capsule or microcapsule adapted for enteric delivery and comprising a plurality of viable non-pathogenic or attenuated pathogenic spores of at least two Clostridium species, wherein said oral pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes or between about 10 9 and about 10 11 viable microbes.
4. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition is effective for treating a Clostridium difficile infection.
5. The oral pharmaceutical composition of claim 1 , wherein oral pharmaceutical composition is lyophilized.
6. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition comprises between about 10 9 and about 10 11 viable microbes.
7. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is in an enteric-coated capsule or an enteric-coated microcapsule.
8. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for recolonizing a dysbiotic enteric microflora in a subject in need thereof.
9. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for treating a disorder associated with the presence of abnormal or an abnormal distribution of gastrointestinal microflora.
10. The oral pharmaceutical composition of claim 9 , wherein said disorder is selected from the group consisting of irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.
11. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for treating a recurrent Clostridium difficile infection.
12. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for treating a regressive disorder in a patient with the presence of abnormal or an abnormal distribution of gastrointestinal microflora, said disorder is selected from the group consisting of autism, Asperger syndrome, Rett syndrome, attention deficit hyperactivity disorder (ADHD), and attention deficit disorder (ADD).
13. The oral pharmaceutical composition of claim 1 , wherein said Clostridium spores are selected from the group consisting of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium carnis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii , and Clostridium villosum.
14. The oral pharmaceutical composition of claim 1 , wherein said Clostridium spores are selected from the group consisting of Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum , and Clostridium butyricum.
15. The oral pharmaceutical composition of claim 3 , wherein oral pharmaceutical composition is lyophilized.
16. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition comprises between about 10 9 and about 10 11 viable microbes.
17. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition is in an enteric-coated capsule or an enteric-coated microcapsule.
18. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition is effective for recolonizing a dysbiotic enteric microflora in a subject in need thereof.
19. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition is effective for treating a disorder associated with the presence of abnormal or an abnormal distribution of gastrointestinal microflora.
20. The oral pharmaceutical composition of claim 19 , wherein said disorder is selected from the group consisting of irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.
21. The oral pharmaceutical composition of claim 3 , wherein said oral pharmaceutical composition is effective for treating a recurrent Clostridium difficile infection.
22. The oral pharmaceutical composition of claim 1 , wherein said oral pharmaceutical composition is effective for treating a regressive disorder in a patient with the presence of abnormal or an abnormal distribution of gastrointestinal microflora, said disorder is selected from the group consisting of autism, Asperger syndrome, Rett syndrome, attention deficit hyperactivity disorder (ADHD), and attention deficit disorder (ADD).
23. The oral pharmaceutical composition of claim 3 , wherein said at least two Clostridium species are selected from the group consisting of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium carnis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii , and Clostridium villosum.
24. The oral pharmaceutical composition of claim 1 , wherein said Clostridium spores are selected from the group consisting of Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum , and Clostridium butyricum .